Funds Support Global Nonprofit’s Mission of Finding a Cure for Duchenne Muscular Dystrophy NEWPORT BEACH, Calif., (September 19, 2023) – CureDuchenne, a leading global nonprofit focused on finding and funding […]
NEWPORT BEACH, Calif., (September 19, 2023) — CureDuchenne, a leading nonprofit organization dedicated to advancing research and improving the lives of individuals affected by Duchenne muscular dystrophy, is proud to […]
Annual Event Features Dinner, Drinks, Raffles, Fall Fashion Show Preview and More to Raise Funds to Help Find a Cure for Duchenne Muscular Dystrophy AUSTIN, Texas (August 15, 2023) – CureDuchenne, […]
Event Has Raised More Than $5.3 Million to Find a Cure for Duchenne Muscular Dystrophy NEWPORT BEACH, Calif., (August 14, 2023) – CureDuchenne, a leading global nonprofit focused on finding […]
NEWPORT BEACH, Calif., (July 31, 2023) — The second annual Cali-RAD Fest (Reggae Against Duchenne) will return to The Beach House in Mission Beach on September 2, 2023, to benefit […]
NEW YORK, June 15, 2023 – CureDuchenne, Muscular Dystrophy Association (MDA), and Parent Project Muscular Dystrophy (PPMD), today announced a collaborative clinical trial grant to test repurposing of the FDA-approved […]
Tickets and Sponsorships Available in Support of Nonprofit Dedicated to Finding and Funding Cure for Duchenne Muscular Dystrophy Knoxville, TN. (June 5, 2023) – Knoxville Brewfest, the city’s most anticipated […]
“CureDuchenne is a leader in funding pioneering research aimed at advancing the best possible therapies for DMD patients, and we value their vote of confidence and financial support of our snRNA-mediated exon skipping platform,” said Jim Burns, Ph.D., Locanabio’s chief executive officer.
My name is Debra Miller, founder and CEO of CureDuchenne, and the mother of an incredible son, Hawken, who has Duchenne muscular dystrophy. I’m here today to represent the voice of patient advocacy organizations serving those impacted by Duchenne – all of whom are in support of the accelerated approval of SRP-9001.